Status: Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Participants needed: 440
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: ExelixisUpdated: Apr 17, 2026Locations: 80
Eligibility criteria
Histologically confirmed, locally advanced/unresectable or metastatic, well-diff... [+4]
Histologically confirmed neuroendocrine carcinomas (including small cell lung ca... [+4]